Seattle, WA, United States of America

Calvin Chan

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 4.4

ph-index = 1

Forward Citations = 13(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Calvin Chan: Innovator in Immune Cell Engineering

Introduction

Calvin Chan is a prominent inventor based in Seattle, WA (US), known for his significant contributions to the field of immune cell engineering. With a total of 4 patents to his name, Chan has been at the forefront of developing methods that enhance the capabilities of immune cells for therapeutic applications.

Latest Patents

One of Chan's latest patents focuses on "Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy." This patent outlines innovative techniques for preparing cells and compositions aimed at genetic engineering and cell therapy. The methods described are designed to streamline the processes of isolation, processing, incubation, and genetic engineering of immune cells, particularly T cells. By employing these methods, a variety of different cell populations can be prepared for adoptive therapy with fewer steps and reduced resource requirements compared to traditional methods.

Career Highlights

Calvin Chan is currently associated with Juno Therapeutics GmbH, where he continues to push the boundaries of cell therapy. His work has been instrumental in advancing the understanding and application of immune cell therapies, which hold great promise for treating various diseases.

Collaborations

Throughout his career, Chan has collaborated with notable colleagues, including Chris Ramsborg and Mark L Bonyhadi. These partnerships have fostered a collaborative environment that enhances innovation and accelerates the development of new therapeutic strategies.

Conclusion

Calvin Chan's contributions to the field of immune cell engineering exemplify the impact of innovative thinking in medical science. His patents and ongoing work at Juno Therapeutics GmbH are paving the way for future advancements in adoptive therapy.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…